Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
Critics say Mylan has been emboldened by the recall of EpiPen’s only competition last fall. —Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. .
40 
Let's personalize your content